NCT07446465 2026-03-03
FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer
Fudan University
Phase 4 Not yet recruiting
Clinical Trials
12 trialsNCT07094893 2026-01-14
ARIEL-ENGIC
Gruppo Oncologico del Nord-Ovest
Phase 4 Not yet recruiting
NCT07158164 2025-11-13
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment
Rutgers, The State University of New Jersey
Phase 4 Recruiting
NCT02366819 2025-06-13
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
University of Chicago
Phase 4 Recruiting
NCT04269369 2020-02-13
Implementation of Pre-emptive Geno- and Phenotyping in 5-Fluorouracil- or Capecitabine-treated Patients
Jessa Hospital
Phase 4 Unknown
NCT01271582 2019-01-29
Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients
Asan Medical Center
Phase 4 Unknown
NCT03084809 2017-03-21
Chemotherapy Combined With CIK Treating Colon Cancer
China Meitan General Hospital
Phase 4 Completed
NCT01641458 2016-02-02
FLOXTOX2
Cantonal Hospital of St. Gallen
Phase 4 Completed
NCT02284529 2014-11-06
Oxaliplatin
Sinphar Pharmaceutical Co., Ltd
Phase 4 Completed
NCT01972503 2013-12-11
Intraoperative Intraportal Chemotherapy Combined With Adjuvant Chemotherapy for Stage II and III Colorectal Cancer
Fudan University
Phase 4 Unknown
NCT00138060 2010-07-20
Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants
Institut de Recherche Clinique sur les Cancers et le Sang
Phase 4 Completed
NCT01023633 2009-12-02
OPTIMOX1 in Chinese mCRC Patients
Nanjing Medical University
Phase 4 Unknown